Dysregulated Kras/YY1/ZNF322A/Shh transcriptional axis enhances neo-angiogenesis to promote lung cancer progression.


Journal

Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395

Informations de publication

Date de publication:
2020
Historique:
received: 27 04 2020
accepted: 02 08 2020
entrez: 15 9 2020
pubmed: 16 9 2020
medline: 29 5 2021
Statut: epublish

Résumé

Angiogenesis enhances cancer metastasis and progression, however, the roles of transcription regulation in angiogenesis are not fully defined. ZNF322A is an oncogenic zinc-finger transcription factor. Here, we demonstrate a new mechanism of

Identifiants

pubmed: 32929330
doi: 10.7150/thno.47491
pii: thnov10p10001
pmc: PMC7481419
doi:

Substances chimiques

Hedgehog Proteins 0
KRAS protein, human 0
Oncogene Proteins 0
SHH protein, human 0
Transcription Factors 0
YY1 Transcription Factor 0
YY1 protein, human 0
ZNF322 protein, human 0
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

10001-10015

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Cancer Res. 2017 Apr 15;77(8):2134-2147
pubmed: 28202523
Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9589-94
pubmed: 21597001
Cancers (Basel). 2016 Feb 15;8(2):
pubmed: 26891329
Cancer Res. 2017 Jan 1;77(1):100-111
pubmed: 27793842
Int J Cancer. 2018 Aug 1;143(3):460-465
pubmed: 29322514
Oncogene. 2017 Oct 12;36(41):5722-5733
pubmed: 28581525
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
Nat Commun. 2019 Sep 20;10(1):4297
pubmed: 31541101
Cancer Res. 2011 Jul 15;71(14):5020-9
pubmed: 21586612
Nature. 2015 Jan 22;517(7535):489-92
pubmed: 25363767
Clin Cancer Res. 2011 Mar 15;17(6):1341-50
pubmed: 21411444
Clin Cancer Res. 2017 May 15;23(10):2377-2381
pubmed: 28073840
Blood. 2014 Apr 10;123(15):2429-37
pubmed: 24472833
Clin Epigenetics. 2019 Jun 19;11(1):92
pubmed: 31217031
Theranostics. 2020 Mar 4;10(9):4183-4200
pubmed: 32226547
Mol Cancer Ther. 2014 Feb;13(2):386-98
pubmed: 24344235
Cell Rep. 2016 Oct 4;17(2):484-500
pubmed: 27705796
Nat Commun. 2017 Feb 21;8:14294
pubmed: 28220783
Cancers (Basel). 2019 Oct 24;11(11):
pubmed: 31652979
Nature. 1983 Jun 2-8;303(5916):396-400
pubmed: 6304521
Proc Natl Acad Sci U S A. 1982 Aug;79(16):4848-52
pubmed: 6289320
Oncotarget. 2014 Dec 15;5(23):12151-65
pubmed: 25432075
Theranostics. 2020 Jun 5;10(16):7335-7350
pubmed: 32641995
Sci Rep. 2014 May 16;4:4995
pubmed: 24833309
Mol Cancer Res. 2016 Oct;14(10):1019-1029
pubmed: 27422710
Nature. 2008 Feb 21;451(7181):1008-12
pubmed: 18288196
Cancer Res. 2007 May 15;67(10):4816-26
pubmed: 17510411
Cell Chem Biol. 2017 Mar 16;24(3):252-280
pubmed: 28286127
Oncogene. 2019 Oct;38(41):6723-6736
pubmed: 31399647
Cytokine Growth Factor Rev. 2016 Oct;31:61-71
pubmed: 27578214
Theranostics. 2018 Jan 1;8(2):423-436
pubmed: 29290818
Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):3499-504
pubmed: 25739959
Front Pharmacol. 2018 Aug 22;9:958
pubmed: 30186180
Cell Commun Signal. 2018 Mar 20;16(1):11
pubmed: 29558958
Am J Pathol. 2012 Jan;180(1):2-11
pubmed: 22056910
Oncogene. 2016 May 5;35(18):2357-69
pubmed: 26279304
Cancer Lett. 2020 Apr 28;476:48-56
pubmed: 32061952
FASEB J. 2009 Jan;23(1):21-33
pubmed: 18772349
Oncogenesis. 2017 Apr 10;6(4):e313
pubmed: 28394354
Cell Death Differ. 2019 Jul;26(7):1283-1298
pubmed: 30258097
Cancer Res. 2019 Feb 1;79(3):625-638
pubmed: 30563891
Genes Dev. 1995 May 15;9(10):1188-98
pubmed: 7758944
Biochem Biophys Res Commun. 2004 Dec 24;325(4):1383-92
pubmed: 15555580

Auteurs

Che-Chung Lin (CC)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

I-Ying Kuo (IY)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Li-Ting Wu (LT)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Wen-Hui Kuan (WH)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Sheng-You Liao (SY)

Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Jayu Jen (J)

Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

You-En Yang (YE)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Cheng-Wei Tang (CW)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Yi-Rong Chen (YR)

Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, 35053, Taiwan.

Yi-Ching Wang (YC)

Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, 70101, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH